Welcome to our dedicated page for Proassurance Cp SEC filings (Ticker: PRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission filings for ProAssurance Corporation (NYSE: PRA), a specialty property and casualty insurance holding company focused on medical professional liability, products liability for medical technology and life sciences, and workers’ compensation insurance. These regulatory documents offer detailed information on ProAssurance’s financial condition, segment performance, governance, and its pending merger with The Doctors Company.
ProAssurance’s periodic reports, such as its Form 10-K and Form 10-Q filings (referenced in the company’s earnings releases and 8-Ks), include consolidated financial statements, segment disclosures for Specialty Property and Casualty, Workers’ Compensation Insurance, Segregated Portfolio Cell Reinsurance, Lloyd’s Syndicate, and Corporate, as well as discussions of key ratios, Non-GAAP measures, and risk factors. Investors use these filings to analyze underwriting results, reserve development, investment income, and capital metrics like book value per share and Non-GAAP adjusted book value per share.
The company’s Form 8-K filings highlight specific material events. In 2025, ProAssurance filed multiple 8-Ks to furnish quarterly earnings releases under Item 2.02, report the June 24, 2025 stockholder vote approving the merger agreement with The Doctors Company under Item 5.07, and describe progress on regulatory milestones such as early termination of the Hart-Scott-Rodino waiting period under Item 8.01. Another 8-K filed in December 2025 under Item 5.02 outlines compensatory arrangements for named executive officers in connection with the merger and explains how these payments relate to Section 280G of the Internal Revenue Code.
On Stock Titan, ProAssurance filings are updated as they are released on EDGAR. AI-powered summaries help explain the contents of lengthy documents, highlight key changes from prior periods, and surface important items such as segment results, merger-related disclosures, and executive compensation arrangements. Users can review Forms 10-K and 10-Q for comprehensive financial information, 8-Ks for transaction and earnings announcements, and other filings that document ProAssurance’s regulatory history and its planned transition to a wholly owned subsidiary of The Doctors Company.
ProAssurance Corporation executive Noreen Dishart, Executive VP and Chief HR Officer, exercised restricted stock units into common shares and had a portion withheld for taxes. On February 25, 2026, she converted 4,588, 5,987, and 3,101 restricted stock units into the same number of common shares at a stated price of $24.47 per share. To cover tax obligations, 5,917 common shares were disposed of as a tax-withholding transaction, leaving her with 27,740 shares of ProAssurance common stock held directly.
ProAssurance Corporation executive Robert David Francis reported multiple equity award transactions. On February 25, 2026, he exercised Restricted Stock Units that converted into 3,226, 8,765, and 5,890 shares of common stock at a stated price of
PROASSURANCE CORP Chief Financial Officer Dana S. Hendricks reported multiple equity award transactions involving restricted stock units and common shares on February 25, 2026. Hendricks exercised several batches of restricted stock units, converting 5,890, 7,686, and 3,981 restricted stock units into the same number of common shares, all reported at a transaction price of $24.47 per share for the common stock entries.
In a separate transaction coded F, Hendricks disposed of 7,623 common shares at a reported price of $24.47 per share to satisfy exercise price or tax obligations. Following these transactions, Hendricks directly owned 45,603 shares of common stock and maintained several outstanding restricted stock unit awards with reported balances of 23,720, 7,686, and 11,778 units, which vest in pro rata installments over future years if employment conditions are met.
ProAssurance Corp President and CEO Edward Rand Jr reported multiple equity award transactions on common stock and restricted stock units. On February 25, 2026, he exercised several batches of restricted stock units into common shares at $24.47 per share and increased his direct common stock holdings.
In connection with these equity events, 30,436 common shares were disposed of to cover tax liabilities, a non–open-market, tax-withholding transaction. Footnotes explain that each restricted stock unit represents a right to one common share that generally vests in equal one-third installments over three-year periods between 2024 and 2029, with accelerated vesting upon death, disability, certain employment terminations, or Compensation Committee action.
ProAssurance Corporation subsidiary president Kevin Merrick Shook reported multiple equity award transactions. On February 25, 2026, he exercised several batches of Restricted Share Units (RSUs), converting them into ProAssurance common stock at a reference price of $24.47 per share, and then disposed of 7,587 shares to cover tax obligations. After these transactions, he directly owned 53,447 shares of common stock.
The RSUs come from the ProAssurance Corporation 2014 Equity Incentive Compensation Plan and generally vest in equal one‑third installments over three years across award cycles spanning 2024–2029, subject to continued employment. Vesting accelerates upon death, disability, or certain employment terminations defined as Good Reason, and RSUs are settled in a mix of shares and cash approximately equal to taxes.
ProAssurance Corp executive Jeffrey Patton Lisenby, Executive Vice-President and General Counsel, exercised restricted stock units into common shares of ProAssurance on February 25, 2026. He acquired 17,557 shares of common stock through derivative exercises at a reference price of $24.47 per share, with 7,615 shares disposed of to cover tax liabilities. Following these transactions, he directly owned 98,286 shares of common stock. The related restricted stock units were granted under the company’s 2014 and 2024 equity incentive plans and generally vest in equal annual installments over three years, with potential accelerated vesting upon death, disability, Good Reason termination, or Compensation Committee action.
ProAssurance Corporation files its annual report detailing its 2025 business and a pending merger with The Doctors Company. For the year, net premiums written were
Gross premiums written were
The company describes its March 2025 Merger Agreement under which it would become a wholly owned subsidiary of The Doctors Company. Shareholders have approved the deal and most U.S. insurance regulatory approvals have been obtained, with California and Pennsylvania still reviewing. ProAssurance continues to anticipate closing by June 30, 2026, subject to remaining conditions.
ProAssurance Corporation reported stronger fourth-quarter and mixed full-year 2025 results while advancing its planned merger with The Doctors Company. For the quarter ended December 31, 2025, net income was $33.4 million, or $0.64 per diluted share, and Non-GAAP operating income was $42.4 million, or $0.82 per diluted share, both more than double the prior year’s quarter.
For full-year 2025, net income was $50.9 million, or $0.99 per diluted share, slightly below 2024, but Non-GAAP operating income rose to $83.9 million, or $1.62 per diluted share, from $50.2 million, or $0.98 per diluted share. The consolidated Non-GAAP combined ratio improved to 104.2% for the year and 90.3% in the fourth quarter, helped by $53.1 million of favorable prior-year reserve development in Medical Professional Liability. Book value per share increased to $26.24 from $23.49, and Non-GAAP adjusted book value per share rose to $27.82.
The company highlighted continued premium rate increases in its Specialty P&C segment and stable retention of 84%. Management reiterated that the merger with The Doctors Company is progressing, with multiple state regulatory approvals obtained and remaining reviews in California and Pennsylvania still pending, and continues to be anticipated to close by June 30, 2026, subject to final regulatory approvals.
AllianceBernstein L.P. filed an amended Schedule 13G to report its beneficial ownership of 1,910,053 shares of ProAssurance Corp common stock, representing 3.7% of the class as of December 31, 2025. AllianceBernstein has sole voting power over 1,578,283 shares and sole dispositive power over 1,910,053 shares, with no shared voting or dispositive power. The shares are held for investment purposes in client discretionary advisory accounts, and AllianceBernstein states they are not held to change or influence control of ProAssurance.
The Vanguard Group has reported a significant ownership position in ProAssurance Corp. As of December 31, 2025, Vanguard beneficially owned 5,299,454 shares of ProAssurance common stock, representing 10.3% of the outstanding class.
Vanguard reports shared voting power over 387,020 shares, with no sole voting power, and shared dispositive power over all 5,299,454 shares. The shares are held for Vanguard’s clients, who have rights to dividends and sale proceeds, and no single client holds more than 5% of the class. Vanguard states the holdings are in the ordinary course of business and not for the purpose of changing or influencing control.
The filing notes an internal realignment effective January 12, 2026, after which certain Vanguard subsidiaries or business divisions are expected to report beneficial ownership separately, while continuing the same investment strategies.